Skip to main content
TipRanks
Go Ultimate75% OFF

Krystal Biotech (KRYS) Ratios

738 Followers

Krystal Biotech Ratios

KRYS's free cash flow for Q3 2026 was $90.25M. For the 2026 fiscal year, KRYS's free cash flow was decreased by $-996.00K and operating cash flow was $91.25M. See a summary of the company’s cash flow.

Financial ratios
RatiosDec 25Dec 24Dec 23Dec 22Dec 21
Liquidity Ratios
Current Ratio9.957.2817.7613.3017.18
Quick Ratio9.567.0217.5513.3017.18
Cash Ratio4.823.3810.835.6113.26
Solvency Ratio1.850.880.42-3.77-2.07
Operating Cash Flow Ratio1.951.21-2.68-3.49-1.86
Short-Term Operating Cash Flow Coverage0.000.000.000.000.00
Net Current Asset Value$ 910.37M$ 632.59M$ 548.20M$ 347.56M$ 409.55M
Leverage Ratios
Debt-to-Assets Ratio0.010.010.010.020.01
Debt-to-Equity Ratio0.010.010.010.020.01
Debt-to-Capital Ratio0.010.010.010.020.01
Long-Term Debt-to-Capital Ratio0.000.000.000.000.00
Financial Leverage Ratio1.091.121.051.071.06
Debt Service Coverage Ratio0.000.000.000.00-44.39
Interest Coverage Ratio0.000.000.000.00-45.76
Debt to Market Cap0.000.000.000.000.00
Interest Debt Per Share0.320.250.300.350.43
Net Debt to EBITDA-2.48-3.073.841.315.03
Profitability Margins
Gross Profit Margin92.61%93.09%93.90%0.00%0.00%
EBIT Margin48.69%35.52%-191.77%0.00%0.00%
EBITDA Margin50.37%37.83%-180.11%0.00%0.00%
Operating Profit Margin41.45%22.61%-216.43%0.00%0.00%
Pretax Profit Margin48.69%32.82%25.44%0.00%0.00%
Net Profit Margin52.64%30.69%21.56%0.00%0.00%
Continuous Operations Profit Margin52.64%30.69%21.56%0.00%0.00%
Net Income Per EBT108.11%93.50%84.76%100.00%100.00%
EBT Per EBIT117.47%145.15%-11.75%96.40%101.90%
Return on Assets (ROA)15.36%8.44%1.34%-25.06%-11.11%
Return on Equity (ROE)16.80%9.42%1.40%-26.80%-11.72%
Return on Capital Employed (ROCE)13.10%6.89%-13.97%-27.42%-11.37%
Return on Invested Capital (ROIC)13.09%6.43%-11.82%-27.34%-11.35%
Return on Tangible Assets15.36%8.44%1.34%-25.06%-11.11%
Earnings Yield2.87%1.99%0.32%-6.93%-4.48%
Efficiency Ratios
Receivables Turnover3.052.771.210.000.00
Payables Turnover8.894.021.670.000.00
Inventory Turnover0.710.760.440.000.00
Fixed Asset Turnover2.461.800.300.000.00
Asset Turnover0.290.280.060.000.00
Working Capital Turnover Ratio0.500.490.110.000.00
Cash Conversion Cycle591.89523.20908.560.000.00
Days of Sales Outstanding119.52131.60302.660.000.00
Days of Inventory Outstanding513.45482.30824.020.000.00
Days of Payables Outstanding41.0890.70218.130.000.00
Operating Cycle632.97613.901126.680.000.00
Cash Flow Ratios
Operating Cash Flow Per Share6.944.32-3.27-3.95-2.16
Free Cash Flow Per Share6.534.17-3.70-6.02-5.24
Dividend Paid and CapEx Coverage Ratio16.8129.12-7.53-1.90-0.70
Capital Expenditure Coverage Ratio16.8129.12-7.53-1.90-0.70
Operating Cash Flow Coverage Ratio21.5117.00-10.97-11.26-5.97
Operating Cash Flow to Sales Ratio0.520.42-1.750.000.00
Free Cash Flow Yield2.65%2.66%-2.99%-7.60%-7.49%
Valuation Ratios
Price-to-Earnings (P/E) Ratio34.8250.21308.15-14.43-22.32
Price-to-Sales (P/S) Ratio18.3415.4266.450.000.00
Price-to-Book (P/B) Ratio5.854.734.333.872.62
Price-to-Free Cash Flow (P/FCF) Ratio37.7737.58-33.49-13.15-13.35
Price-to-Operating Cash Flow Ratio35.5336.29-37.93-20.08-32.39
Price-to-Earnings Growth (PEG) Ratio0.270.07-2.87-0.19-0.27
Enterprise Value Multiple33.9237.68-33.06-15.98-18.41
Enterprise Value6.65B4.14B3.02B1.87B1.22B
EV to EBITDA33.9237.68-33.06-15.98-18.41
EV to Sales17.0914.2659.540.000.00
EV to Free Cash Flow35.2034.75-30.00-12.16-10.49
EV to Operating Cash Flow33.1033.56-33.99-18.56-25.44
Tangible Book Value Per Share42.1433.1028.6820.4926.74
Shareholders’ Equity Per Share42.1433.1028.6820.4926.74
Tax and Other Ratios
Effective Tax Rate-0.080.060.150.000.00
Revenue Per Share13.4410.161.870.000.00
Net Income Per Share7.083.120.40-5.49-3.13
Tax Burden1.080.940.851.001.00
Interest Burden1.000.92-0.131.161.02
Research & Development to Revenue0.150.180.920.000.00
SG&A to Revenue0.380.390.000.000.00
Stock-Based Compensation to Revenue0.140.170.790.000.00
Income Quality0.981.38-8.120.720.69

Currency in USD